Download PDF
Semin Thromb Hemost 2019; 45(02): 171-179
DOI: 10.1055/s-0039-1678719
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

To Maintain or Cease Non–Vitamin K Antagonist Oral Anticoagulants Prior to Minimal Bleeding Risk Procedures: A Review of Evidence and Recommendations

Yvonne Brennan
1   Department of Haematology, Westmead Hospital, Sydney, Australia
,
Emmanuel J. Favaloro
2   Diagnostic Haemostasis Laboratory, Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, Australia
3   Sydney Centres for Thrombosis and Haemostasis, Westmead, Australia
,
Jennifer Curnow
1   Department of Haematology, Westmead Hospital, Sydney, Australia
3   Sydney Centres for Thrombosis and Haemostasis, Westmead, Australia
4   Sydney Medical School, The University of Sydney, Sydney, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
11 February 2019 (online)

    Permissions and Reprints

Abstract

For procedures associated with minimal bleeding risk, there are data and experience to support the practice of continuing vitamin K antagonists rather than interrupting therapy, to prevent exposing patients to the undue risk of developing thromboembolism during anticoagulation cessation. Despite the increasing use of non–vitamin K oral anticoagulants (NOACs), there is little evidence to guide the management of these drugs around minimal bleeding risk procedures. This review examines and discusses the major society guidelines and recommendations addressing the management of NOACs around minimal bleeding risk procedures. Additionally, it summarizes the existing evidence, and highlights the gaps in knowledge where evidence is not yet available. Finally, recommendations are made to assist the proceduralist deal with this area of limited evidence.

Keywords

Non–vitamin K oral anticoagulants - direct oral anticoagulants - anticoagulation - surgery - minimal bleeding risk - dental procedure - dermatologic surgery

Statement of Limitations

As searches were limited to the PubMed database and the English language, we could not be certain that the search was all inclusive for all guidelines, or all the “minimal bleeding risk procedures” potentially covered, but as the search uncovered guidelines from the major societies, and a range of anticipated “minimal bleeding risk procedures” were covered, we believe the report to reflect a fair representation of the literature.


 

  • References

  • 1 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 2 Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke 2017; 12 (06) 589-596
    CrossrefPubMedGoogle Scholar
  • 3 Hicks T, Stewart F, Eisinga A. NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. Open Heart 2016; 3 (01) e000279
    CrossrefPubMedGoogle Scholar
  • 4 Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016; 41 (01) 206-232
    CrossrefPubMedGoogle Scholar
  • 5 Food and Drug Administration. Pradaxa approval letter. 2010. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022512s000ltr.pdf . Accessed August 23, 2018
    PubMedGoogle Scholar
  • 6 Food and Drug Administration. Approval Letter - Andexxa. 2018. Available at: www.fda.gov/downloads/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/ucm606693.pdf . Accessed August 23, 2018
    PubMedGoogle Scholar
  • 7 Ansell JE, Bakhru SH, Laulicht BE. , et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 2017; 117 (02) 238-245
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 ClinicalTrials.gov. Phase 2 study of apixaban reversal by ciraparantag as measured by WBCT. Available at: https://clinicaltrials.gov/ct2/show/NCT03288454?term=NCT03288454&rank=1 . Accessed August 23, 2018
    PubMedGoogle Scholar
  • 9 Favaloro EJ, Pasalic L, Curnow J, Lippi G. Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): advantages, limitations and future challenges. Curr Drug Metab 2017; 18 (07) 598-608
    PubMedGoogle Scholar
  • 10 Gosselin RC, Adcock DM, Bates SM. , et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2018; 118 (03) 437-450
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Douketis JD, Spyropoulos AC, Anderson JM. , et al. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study for patients on a direct oral anticoagulant who need an elective surgery or procedure: design and rationale. Thromb Haemost 2017; 117 (12) 2415-2424
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Douketis JD, Spyropoulos AC, Spencer FA. , et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e326S-e350S
    CrossrefPubMedGoogle Scholar
  • 13 Raval AN, Cigarroa JE, Chung MK. , et al; American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Quality of Care and Outcomes Research. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation 2017; 135 (10) e604-e633
    PubMedGoogle Scholar
  • 14 Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost 2016; 14 (05) 875-885
    CrossrefPubMedGoogle Scholar
  • 15 Tran H, Joseph J, Young L. , et al; Australasian Society of Thrombosis and Haemostasis. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Intern Med J 2014; 44 (06) 525-536
    CrossrefPubMedGoogle Scholar
  • 16 Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013; 368 (22) 2113-2124
    CrossrefPubMedGoogle Scholar
  • 17 Albaladejo P, Bonhomme F, Blais N. , et al; French Working Group on Perioperative Hemostasis (GIHP). Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015. Anaesth Crit Care Pain Med 2017; 36 (01) 73-76
    CrossrefPubMedGoogle Scholar
  • 18 Steffel J, Verhamme P, Potpara TS. , et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace 2018; 20: 1231-1242
    CrossrefPubMedGoogle Scholar
  • 19 Garcia D, Alexander JH, Wallentin L. , et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood 2014; 124 (25) 3692-3698
    CrossrefPubMedGoogle Scholar
  • 20 Beyer-Westendorf J, Gelbricht V, Förster K. , et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35 (28) 1888-1896
    CrossrefPubMedGoogle Scholar
  • 21 Healey JS, Eikelboom J, Douketis J. , et al; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012; 126 (03) 343-348
    CrossrefPubMedGoogle Scholar
  • 22 Shaw JR, Woodfine JD, Douketis J, Schulman S, Carrier M. Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Res Pract Thromb Haemost 2018; 2 (02) 282-290
    CrossrefPubMedGoogle Scholar
  • 23 Chan FKL, Goh KL, Reddy N. , et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. Gut 2018; 67 (03) 405-417
    CrossrefPubMedGoogle Scholar
  • 24 Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124 (15) 2450-2458
    CrossrefPubMedGoogle Scholar
  • 25 Brekelmans MP, Scheres LJ, Bleker SM. , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thromb Haemost 2017; 117 (04) 809-815
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Ferreira M, Barsam S, Patel JP. , et al. Heavy menstrual bleeding on rivaroxaban. Br J Haematol 2016; 173 (02) 314-315
    CrossrefPubMedGoogle Scholar
  • 27 Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017; 15 (11) 1674-1683.e3
    CrossrefPubMedGoogle Scholar
  • 28 Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8 (01) 202-204
    CrossrefPubMedGoogle Scholar
  • 29 Food and Drug Administration. Savaysa NDA approval. 2015. Available at: www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/206316Orig2s000ltr.pdf . Accessed August 23, 2018
    PubMedGoogle Scholar
  • 30 Gómez-Moreno G, Fernández-Cejas E, Aguilar-Salvatierra A, de Carlos F, Delgado-Ruiz RA, Calvo-Guirado JL. Dental implant surgery in patients in treatment by dabigatran. Clin Oral Implants Res 2018; 29 (06) 644-648
    CrossrefPubMedGoogle Scholar
  • 31 Brennan Y, Gu Y, Favoloro EJ. , et al. Dental extractions on NOACs without stopping therapy (DENTST) study: interim analysis. Presented at HAA Annual Scientific Meeting; October 29–November 1, 2017; Sydney, Australia
    PubMedGoogle Scholar
  • 32 Brennan Y, Gu Y, Favoloro EJ. , et al. Dental extractions on NOACs without stopping therapy (DENTST) study: interim analysis. Res Pract Thromb Haemost 2017; 1 (Suppl. 01) 986
    PubMedGoogle Scholar
  • 33 Brennan Y, Gu Y, Favoloro EJ. , et al. Dental extractions on NOACs without stopping therapy (DENTST) study: interim analysis. Presented at the 9th Congress of the Asian-Pacific Society on Thrombosis and Hemostasis; October 6–9, 2016; Taipei, Taiwan
    PubMedGoogle Scholar
  • 34 Chang TW, Arpey CJ, Baum CL. , et al. Complications with new oral anticoagulants dabigatran and rivaroxaban in cutaneous surgery. Dermatol Surg 2015; 41 (07) 784-793
    CrossrefPubMedGoogle Scholar
  • 35 Heard LK, Shanahan C, Maggio KL. Complications with new oral anticoagulants dabigatran and rivaroxaban in cutaneous surgery. Dermatol Surg 2017; 43 (04) 597-599
    CrossrefPubMedGoogle Scholar
  • 36 Cheung JJC, Liu S, Li KKW. Phacoemulsification cataract surgery in patients receiving novel oral anticoagulant medications. Int Ophthalmol 2018 Doi: 10.1007/s10792-018-0862-x
    PubMedGoogle Scholar
  • 37 Heublein V, Pannach S, Daschkow K, Tittl L, Beyer-Westendorf J. Gastrointestinal endoscopy in patients receiving novel direct oral anticoagulants: results from the prospective Dresden NOAC registry. J Gastroenterol 2018; 53 (02) 236-246
    CrossrefPubMedGoogle Scholar
  • 38 Westerman ME, Scales JA, Sharma V, Gearman DJ, Ingimarsson JP, Krambeck AE. The effect of anticoagulation on bleeding-related complications following ureteroscopy. Urology 2017; 100: 45-52
    CrossrefPubMedGoogle Scholar
  • 39 Culkin DJ, Exaire EJ, Green D. , et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol 2014; 192 (04) 1026-1034
    CrossrefPubMedGoogle Scholar
  • 40 Douketis JD, Berger PB, Dunn AS. , et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl): 299S-339S
    CrossrefPubMedGoogle Scholar
  • 41 Yui JC, Preskill C, Greenlund LS. Arthrocentesis and joint injection in patients receiving direct oral anticoagulants. Mayo Clin Proc 2017; 92 (08) 1223-1226
    CrossrefPubMedGoogle Scholar
  • 42 Nairooz R, Sardar P, Payne J, Aronow WS, Paydak H. Meta-analysis of major bleeding with uninterrupted warfarin compared to interrupted warfarin and heparin bridging in ablation of atrial fibrillation. Int J Cardiol 2015; 187: 426-429
    CrossrefPubMedGoogle Scholar
  • 43 Calkins H, Hindricks G, Cappato R. , et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. J Arrhythm 2017; 33 (05) 369-409
    PubMedGoogle Scholar
  • 44 Cappato R, Marchlinski FE, Hohnloser SH. , et al; VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015; 36 (28) 1805-1811
    CrossrefPubMedGoogle Scholar
  • 45 Calkins H, Nordaby M. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 2017; 377 (05) 495-496
    PubMedGoogle Scholar
  • 46 Kirchhof P, Haeusler KG, Blank B. , et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J 2018; 39 (32) 2942-2955
    CrossrefPubMedGoogle Scholar
  • 47 Brieger D, Amerena J, Attia J. , et al; NHFA CSANZ Atrial Fibrillation Guideline Working Group. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung Circ 2018; 27 (10) 1209-1266
    CrossrefPubMedGoogle Scholar
  • 48 Birnie DH, Healey JS, Wells GA. , et al; BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013; 368 (22) 2084-2093
    CrossrefPubMedGoogle Scholar
  • 49 Kumbhani DJ. A randomised controlled trial of continued versus interrupted direct oral anti-coagulant at the time of device surgery - BRUISE CONTROL-2. 2017. Available at: http://www.acc.org/latest-in-cardiology/clinical-trials/2017/11/10/21/56/bruise-control-2 . Accessed April 23, 2018
    PubMedGoogle Scholar
  • 50 Patatanian E, Fugate SE. Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. Ann Pharmacother 2006; 40 (12) 2205-2210
    CrossrefPubMedGoogle Scholar
  • 51 American Dental Association. Anticoagulant and antiplatelet medications and dental procedures. 2015. Available at: https://www.ada.org/en/member-center/oral-health-topics/anticoagulant-antiplatelet-medications-and-dental-#.WqTDI3N4ZdI . Accessed August 23, 2018
    PubMedGoogle Scholar
  • 52 Scottish Dental Clinical Effectiveness Programme. Management of dental patients taking anticoagulants or antiplatelet drugs: dental clinical guidance. Available at: http://www.sdcep.org.uk/published-guidance/anticoagulants-and-antiplatelets . Accessed August 23, 2018
    PubMedGoogle Scholar
  • 53 Acosta RD, Abraham NS, Chandrasekhara V. , et al; ASGE Standards of Practice Committee. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016; 83 (01) 3-16
    CrossrefPubMedGoogle Scholar
  • 54 Veitch AM, Vanbiervliet G, Gershlick AH. , et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy 2016; 48 (04) c1
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 FSRH Clinical Effectiveness Unit. CEU statement: management of women taking anticoagulants or antiplatelet medications who request intrauterine contraception or subdermal implants. 2017. Available at: www.fsrh.org/news/new-guidance-on-management-of-anticoagulants-or-antiplatelet . Accessed April 8, 2018
    PubMedGoogle Scholar
  • 56 Patel IJ, Davidson JC, Nikolic B. , et al; Standards of Practice Committee, with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement; Standards of Practice Committee of the Society of Interventional Radiology. Addendum of newer anticoagulants to the SIR consensus guideline. J Vasc Interv Radiol 2013; 24 (05) 641-645
    CrossrefPubMedGoogle Scholar
  • 57 Yagyuu T, Kawakami M, Ueyama Y. , et al. Risks of postextraction bleeding after receiving direct oral anticoagulants or warfarin: a retrospective cohort study. BMJ Open 2017; 7 (08) e015952
    CrossrefPubMedGoogle Scholar
  • 58 Patel JP, Woolcombe SA, Patel RK. , et al. Managing direct oral anticoagulants in patients undergoing dentoalveolar surgery. Br Dent J 2017; 222 (04) 245-249
    CrossrefPubMedGoogle Scholar
  • 59 Mauprivez C, Khonsari RH, Razouk O, Goudot P, Lesclous P, Descroix V. Management of dental extraction in patients undergoing anticoagulant oral direct treatment: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol 2016; 122 (05) e146-e155
    CrossrefPubMedGoogle Scholar
  • 60 Morimoto Y, Yokoe C, Imai Y, Sugihara M, Futatsuki T. Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants. J Dent Sci 2016; 11: 59-64
    CrossrefPubMedGoogle Scholar
  • 61 Gómez-Moreno G, Aguilar-Salvatierra A, Fernández-Cejas E, Delgado-Ruiz RA, Markovic A, Calvo-Guirado JL. Dental implant surgery in patients in treatment with the anticoagulant oral rivaroxaban. Clin Oral Implants Res 2016; 27 (06) 730-733
    CrossrefPubMedGoogle Scholar
  • 62 Clemm R, Neukam FW, Rusche B, Bauersachs A, Musazada S, Schmitt CM. Management of anticoagulated patients in implant therapy: a clinical comparative study. Clin Oral Implants Res 2016; 27 (10) 1274-1282
    CrossrefPubMedGoogle Scholar